Stock News

Four reporting periods are affected, and management is reassessing liquidity because collection from Scilex is uncertain.

Adjusted EPS guidance rises to US$18.30 to US$18.70 as stronger cash generation accompanies higher capital spending.

Newmont's cost outlook and Agnico Eagle's Oct. 28 results offer company tests as gold investors await the Federal Reserve's decision.

The payment represents 25 per cent of the development contract value, following customer approval by the end of the third quarter.

Direct stablecoin minting and redemption remain planned, while the companies explore supply chain finance with C2FO.

A recent reverse split rules out a 180-day compliance period, while Enlivex says a timely hearing request would preserve trading pending the hearing.

US$187.7M in cash supports planned operations as two fully enrolled autoimmune trials approach readouts and a third study awaits its start.

Australian government lenders back part of a proposed A$200 million debt package, with commercial financing and final approvals still required.

CoreWeave's Oct. 27 announcement gives no local customer revenue, project costs or billing dates for the Copenhagen deployment.

The South Texas satellite plant and first wellfield are built, with uranium extraction expected shortly after receipt of the final permit.

A planned 72-participant study will test four subcutaneous doses, with safety and tolerability assessed over 48 weeks.

Profit fell from US$505 million a year earlier, while cash, stablecoins and Treasuries reached US$4.9 billion.

Eight holes outlined mineralization across 200 metres of strike at Hatchet Lake South, with follow-up targets to the north and south.

Adjusted operating income turned positive, but an insurance benefit lifted cash generation and the IFRS net loss reached C$50.8 million.

The 523-patient study met its progression-free survival endpoint, but Pfizer withheld the comparative effect size and a filing date.

A 21.75-metre drill interval grades 2.73 grams per tonne, while assays from 44 holes remain pending at the Yukon project.

The initial program will test strike extensions and infill the main zone under a permit for approximately 5,000 metres.

Perpetua must match the Army's contribution, while later exploration phases depend on results, permitting and further funding approvals.

RAM's work includes electrical upgrades and commissioning support, with mill refurbishment targeted for the fourth quarter of 2027.

The proposed hardware and software combination is expected to close in the first half of 2027, subject to regulatory approvals.

About 60,000 employees are reportedly eligible, with decisions due in early December and departures set for Dec. 31.

CFTC figures through Oct. 20 show managed-money net longs fell 28.2 per cent, leaving later selling outside the positioning snapshot.

Class C certification supports continued EU access beyond the 2028 transition deadline and covers the quality management system.

Common-stock cash would arrive at forward settlement, while a proposed Class C sale program has no agreement or settled terms.

Four of 16 evaluable patients responded to lorigerlimab as the company enrols a lower-dose cohort after significant treatment-related toxicity.

The program will test domestic carbon composites for high-temperature defence systems, but payment terms and a testing deadline remain undisclosed.

RESOLVE will test symptom recovery and hospitalization in high-risk adults, starting with at least 200 patients in its Phase 2b portion.

The intercept lies 60 metres up-dip from a historical hole inside the inferred resource, supporting plans to upgrade portions to indicated.

The 541-patient DYNASTY-Breast02 trial met its primary endpoint, but the partners say potential patient benefit is limited.

Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.

Pumitamig plus docetaxel showed early activity after immunotherapy and chemotherapy, but the Phase 2 study had no control arm.

Severe or worse treatment-related adverse events affected 72.1 per cent across expansion cohorts; FDA talks are planned for 2027.

The uncontrolled first-line analyses support continued development, with randomized SUNRAY-01 results expected in the first half of 2027.

Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.

Five of 13 patients reached immunologic remission at 12 weeks, while higher-dose cohorts and longer follow-up will guide development.

USW Local 7619 represents about 1,200 workers at the B.C. copper operation, whose production loss has not been quantified.

A US$1.2 billion agreement spans 2026 to 2030, while a one-time tariff refund lifted the September quarter’s reported earnings.

Proprietary bitcoin holdings remained at zero as of Oct. 23, while the update omitted sale prices and cash proceeds.

The California services acquisition would close in two stages, with cash, a seller note and an earnout subject to separate utility approvals.

New applications came in below a 200,000 forecast, while continuing claims increased by 25,000 in the Labor Department's weekly report.